3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
73
Neoplasm Metastasis
30
Kidney Neoplasms
26
Neoplasms
19
Breast Neoplasms
14
Prostatic Neoplasms
12
Urinary Bladder Neoplasms
10
Melanoma
9
Gastrointestinal Stromal Tumors
9
Brain Neoplasms
9
Glioblastoma
8
Sarcoma
7
Carcinoma, Non-Small-Cell Lung
7
Liver Neoplasms
6
Carcinoma, Hepatocellular
6
Recurrence
5
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Esophageal Neoplasms
5
Colorectal Neoplasms
5
Thyroid Neoplasms
4
Solid Tumors
4
Osteosarcoma
4
Lung Neoplasms
4
Leukemia, Myeloid, Acute
4
Adenocarcinoma
4
Uveal Melanoma
3
Thymoma
3
Stomach Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Interventions
Capecitabine
6
Irinotecan
5
Fluorouracil
5
Cisplatin
5
Oxaliplatin
4
Leucovorin
4
Gemcitabine
4
apatinib
3
Sorafenib
3
Bevacizumab
3
tislelizumab
2
pembrolizumab
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cyclophosphamide
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
lutetium Lu 177 dotatate
1
huachansu
1
halofantrine
1
guadecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Digestive System Neoplasms
×
Sunitinib
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled